T1	Participants 869 1105	Women, aged 18-34 years, with no contraindications to the use of combined OCs, were randomized to three cycles of treatment with a CVR delivering NES/EE (150/15 microg/day) or a combined OC providing LNG and EE (150/30 microg per tablet
T2	Participants 1679 1740	47 women randomized, 45 completed the study (CVR: 23; OC: 22)
